UK scientists have developed a saliva test that analyzes DNA for 130 genetic mutations linked to prostate cancer risk. The goal is to identify men at highest genetic risk and refer them for MRI scans and biopsies, potentially detecting aggressive cancers early that current methods often miss.
In a study of men aged 55–69:
- 745 high-risk men were invited for further testing
- 187 were diagnosed with prostate cancer
- 103 had high-risk tumors, with 74 not detectable by standard screening
The test is not yet proven to save lives or improve quality of life, and it could take years before routine NHS use. Experts stress the need for further studies, particularly among ethnically diverse groups, as Black men face double the risk.
While promising, questions remain about cost, timing, and clinical impact. The test will now be part of the larger Transform trial to explore future screening strategies.